The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day

WASHINGTON, DC, March 28, 2018 -- The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming sixth annual Cell & Gene Therapy Investor Day, taking place April 17, 2018 in New York City. This event, co-hosted by Chardan, PNC Healthcare, Raymond James, and Solebury Trout, provides institutional, strategic, and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.

This year's Cell & Gene Therapy Investor Day is expected to attract more than 350 attendees, including nearly 200 active investors and analysts. With presentations from more than 35 of the sector’s most promising companies, along with panels and fireside chats by the field's foremost thought leaders, this one-day meeting explores how cell and gene therapies are impacting key therapeutic areas, including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair, and neurodegenerative diseases. 

2018 Panel Sessions and Speakers:

Featured Fireside Chat

• Gbola Amusa, M.D., Partner, Director of Research and Head of Healthcare Research, Chardan (moderator)
• Katherine High, M.D., President and Head of Research and Development, Spark Therapeutics

Panel I: Technology Trends: Leading Platforms Across the Cell and Gene Sector

• Amy DuRoss, CEO, Vineti (moderator)
• James Noble, CEO, Adaptimmune
• Bob Smith, SVP, Global Gene Therapy Business, Pfizer

Panel II: The Immuno-Oncology Pipeline for Liquid and Solid Tumors

• Robert Preti, Ph.D., President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector (moderator)
• Samuele Butera, Global Cell and Gene Therapies Business Leader, Novartis Oncology
• Jennifer Butler, Chief Commercial Officer and Head of US, Tessa Therapeutics
• Derrell Porter, M.D., SVP and Global Commercial Head, Atara Biotherapeutics
• Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio

Panel III: Gene Therapy for Rare Diseases

• Ren Benjamin, Ph.D., SVP and Senior Biotechnology Analyst, Raymond James (moderator)
• Timothy Miller, Ph.D., President and CEO, Abeona Therapeutics
• Matt Patterson, CEO, Audentes Therapeutics
• Arthur Tzianabos, Ph.D., CEO, Homology Medicines

2018 Presenting Companies:
4D Molecular Therapeutics; Adaptimmune; Adverum Biotechnologies; AGTC; Avery Therapeutics; BioCardia; bluebird bio; B-MoGen Biotechnologies; Brainstorm Cell Therapeutics; Capricor Therapeutics; Celixir; Cellerant Therapeutics; Cynata Therapeutics; Fibrocell; Frequency Therapeutics; Histogen; Histogenics; inRegen; Iovance Biotherapeutics; Kiadis Pharma; LogicBio; Mesoblast; Miromatrix; MolMed S.p.A.; Neuralstem; Orchard Therapeutics; Oxford BioMedica; Precision BioSciences; Regenerex; ReNeuron; Sernova Corp.; Synpromics; Thrive Bioscience; Tmunity; Vericel; and ViaCyte. 

Full agenda and other details are available at www.arminvestorday.com. 

Sponsors for this year’s event include Cognate BioServices; Cryoport; Crossover Search; CTI Clinical Trial & Consulting; Defined Health; Kawasaki; KBI Biopharma; Lonza; Medpace; and PCT, a Hitachi Group Company. Marketing partners include Antenna Group and Edison.

Credentialed investors and life science strategic partners can indicate their interest in attending here. Members of the media interested in attending are asked to please contact Lyndsey Scull at [email protected].

The event will be held April 17, 2018, beginning at 7:30am at The Metropolitan Club, One East 60th Street, New York, NY 10022.

About The Alliance for Regenerative Medicine:
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Lyndsey Scull
202 213 7086
[email protected]